-
Product Insights
AXA IM Alts/ Grupo Lar – Zaragoza Socio-Health Complex Development – Aragon
The AXA IM Alts/ Grupo Lar – Zaragoza Socio-Health Complex Development – Aragon involves the construction of a socio-health hub senior residential complex in Zaragoza, Aragon, Spain. Equip yourself with the essential tools needed to make informed and profitable decisions with our AXA IM Alts/ Grupo Lar – Zaragoza Socio-Health Complex Development – Aragon report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-21 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-21 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-21 in Refractory Multiple Myeloma Drug Details: IM-21 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-19 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-19 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-19 in Follicular Lymphoma Drug Details: IM-19 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Malignant Mesothelioma Drug Details: Tazemetostat hydrobromide (Tazverik) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Follicular Lymphoma Drug Details: Ibrutinib (Imbruvica) is an anti-neoplastic agent....
-
Product Insights
Anumar Berg im Gau Solar PV Park, Germany
Empower your strategies with our Anumar Berg im Gau Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of the project’s core details and stages of...
-
Company Insights
Aviva – Digital Transformation Strategies
Aviva Digital Transformation Strategies Overview Aviva is strengthening its focus on the use of innovative technologies to enhance its digital capabilities. AI, big data, insurtech, regtech, and cyber insurance are among the technologies the company is concentrating on. The annual ICT spending of Aviva is estimated at $506.5 million for 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Aviva is a multinational insurance and financial services group offering...
-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments · Sustained Release Injectable...